Latest news with #FDA-compliant
Time Business News
4 days ago
- Business
- Time Business News
PVDF Pipe Fittings Supplier in UAE
When it comes to high-performance piping systems in industrial environments, PVDF (Polyvinylidene Fluoride) pipe fittings have earned a reputation for their exceptional chemical resistance, thermal stability, and mechanical strength. In the UAE, one name stands out as a reliable and trusted source of industrial-grade PVDF piping components — PETRON THERMOPLAST FZ-LLC. As a leading PVDF pipe fittings supplier in the UAE, PETRON THERMOPLAST FZ-LLC specializes in providing premium-quality thermoplastic piping solutions designed to meet the demanding needs of industries like chemical processing, pharmaceuticals, water treatment, semiconductors, and food & beverage. PVDF is a highly non-reactive and pure thermoplastic fluoropolymer, known for its unique set of properties that make it ideal for aggressive and high-purity applications. It offers: Excellent chemical resistance to acids, bases, and organic solvents to acids, bases, and organic solvents High thermal stability , capable of withstanding temperatures up to 150°C , capable of withstanding temperatures up to 150°C UV and weather resistance , making it suitable for outdoor use , making it suitable for outdoor use Low permeability and superior mechanical strength and superior mechanical strength Non-toxic and FDA-compliant, suitable for hygienic applications Whether it's transporting corrosive fluids or maintaining ultra-pure water lines, PVDF pipe fittings offer unmatched reliability in critical systems. PETRON THERMOPLAST FZ-LLC has established itself as a premier supplier of industrial thermoplastic solutions in the Middle East, particularly in the United Arab Emirates (UAE). With a comprehensive inventory, technical expertise, and a commitment to customer satisfaction, we have become the go-to choice for industries seeking PVDF piping solutions that deliver both performance and longevity. Our Core Strengths: Wide Range of PVDF Fittings From elbows, tees, and reducers to couplings, valves, and flanges — we stock a complete range of PVDF pipe fittings that meet international standards such as ASTM, DIN, and ISO. From elbows, tees, and reducers to couplings, valves, and flanges — we stock a complete range of PVDF pipe fittings that meet international standards such as ASTM, DIN, and ISO. High Quality & Certified Products Our PVDF fittings are manufactured from virgin-grade materials and conform to stringent quality controls. They are tested for pressure, temperature, and chemical compatibility. Our PVDF fittings are manufactured from virgin-grade materials and conform to stringent quality controls. They are tested for pressure, temperature, and chemical compatibility. Fast Delivery Across UAE & GCC Strategically located in the UAE, PETRON THERMOPLAST FZ-LLC ensures quick delivery to all Emirates and neighboring GCC countries, supporting urgent project needs. Strategically located in the UAE, PETRON THERMOPLAST FZ-LLC ensures quick delivery to all Emirates and neighboring GCC countries, supporting urgent project needs. Technical Support & Custom Solutions Our team of engineers and piping experts can assist with product selection, system design, and installation support to optimize your pipeline efficiency. PVDF pipe fittings are widely used in various sectors where material integrity and corrosion resistance are paramount. PETRON THERMOPLAST FZ-LLC supplies to key industries including: PVDF's inertness makes it ideal for handling corrosive chemicals, acids, and solvents. Our fittings are used in process lines, storage tanks, and scrubber systems. Water & Wastewater Treatment Our PVDF fittings are used in systems requiring high purity and long-term reliability, such as demineralized water lines, RO plants, and effluent treatment systems. Pharmaceutical & Biotechnology PETRON supplies FDA-compliant PVDF fittings for clean room environments, WFI (Water for Injection) systems, and other sterile processing pipelines. Semiconductor Manufacturing High purity and low contamination are essential in semiconductor fabs. Our PVDF solutions support ultra-clean fluid transport in chip manufacturing. PVDF's hygienic properties make it suitable for food contact applications. Our fittings are easy to clean, non-toxic, and compliant with food safety regulations. At PETRON THERMOPLAST FZ-LLC, we stock a diverse portfolio of PVDF fittings in various sizes and configurations to suit any industrial application. Our offerings include: PVDF Elbows (90°, 45°) PVDF Tees (Equal & Reducing) PVDF Reducers (Concentric & Eccentric) PVDF End Caps and Plugs PVDF Socket & Butt Fusion Fittings PVDF Ball Valves and Diaphragm Valves PVDF Flanges and Unions PVDF Pipe Saddles and Clamps PETRON THERMOPLAST FZ-LLC is committed to delivering only the highest-quality PVDF products that conform to international safety and performance standards. Our products undergo rigorous inspection and testing to ensure: Resistance to pressure and temperature fluctuations Compatibility with a broad range of chemicals Dimensional accuracy and secure fit Long service life in harsh conditions As an industrial solutions provider, we go beyond just being a supplier. Here's what makes us stand out: Experienced team with deep industry knowledge with deep industry knowledge Stock availability for quick turnaround for quick turnaround Technical guidance for system integration for system integration Competitive pricing without compromising on quality without compromising on quality After-sales support and project follow-up Looking for a reliable PVDF pipe fittings supplier in the UAE? Partner with PETRON THERMOPLAST FZ-LLC for superior products, expert advice, and dependable service. TIME BUSINESS NEWS
Tatler Asia
09-06-2025
- Health
- Tatler Asia
How &you is rethinking digital healthcare to fit Southeast Asian realities
You emphasise working only with FDA-compliant partners. Can you share how you vet these partners and ensure ongoing compliance? EE: We're lucky to have one of the country's top medical players as a partner, and all our doctors are personally vetted by her, professionals with proven track records and strong patient relationships. On the product side, we work with the best compounding pharmacy in the Philippines: locally produced, family-owned and known for top-grade ingredients. We could cut corners to boost margins, but we're here for the long game—focused on trust, quality and long-term care. What has the public response been like since your launch? EE: The public response since the launch has been overwhelmingly positive. Thousands joined our waitlist early on, and we've seen strong demand from day one. There's still a long way to go, but it's been a very promising start. How does &you aim to transform the healthcare experience in the Philippines? Do you see it succeeding in the way you imagine? EE: This is just the beginning. While we've started with digital medical services, the vision is much bigger—to build a full health and wellness ecosystem in the Philippines. That means not just tech, but also retail, in-person healthcare, and real-world experiences that make care feel more human and accessible. The entire category has huge room for improvement, and we see &you playing a major role in shaping what the future of healthcare looks like here. NOW READ The health benefits of durians, according to a nutritionist The Singapore startup using AI to transform traditional health screenings 9 Filipina-founded femtech companies breaking the stigma around reproductive health
Associated Press
04-06-2025
- Business
- Associated Press
Global Technologies, LTD Announces Strategic Pivot and New Agreements in Health & Wellness Sector
Greensboro, NC, June 04, 2025 (GLOBE NEWSWIRE) -- Global Technologies, LTD (OTCPK: GTLL), a public, multi-operational company focused on innovation in health and wellness, recently announced corporate developments and commercial milestones signaling a bold pivot in strategy and leadership. Over the past 90 days, GTLL has responded proactively to external FDA regulatory shifts that disrupted several industry sectors, including GLP-1 compounding and semaglutide supply. These changes catalyzed GTLL's sharpened focus on the digital health and wellness market, prompting operational streamlining and a commitment to scalable, revenue-focused platforms—particularly through its newly launched subsidiary, Primecare Supply, LLC. Launch of Primecare Supply and Execution of Key Agreements As disclosed in its May 30, 2025 Form 8-K filing, GTLL formally launched Primecare Supply, LLC and executed two transformative commercial agreements: These agreements position Primecare—and GTLL—at the forefront of compliant pharmaceutical distribution and digital wellness innovation. Leadership Appointments and Strategic Realignment In line with the Company's refined strategy, H. Wyatt Flippen has been officially appointed Chairman of the Board in addition to his role as Chief Executive Officer. Concurrently, GTLL has removed the President of its clean energy subsidiary, GOe3, LLC, to allow for a full transition away from non-core operations in the EV sector. 'We are building a business that's leaner, more focused, and directly aligned with FDA-compliant pharmaceutical distribution and digital wellness innovation,' said Flippen. 'These agreements and leadership changes reflect our resolve to reduce complexity, expand into higher-growth sectors, and deliver long-term shareholder value.' A Clearer Path Ahead GTLL is aggressively expanding its offerings in consumer-facing wellness plans and therapeutic products, leveraging both traditional partnerships and digital infrastructure. The Company is now fully aligned around the growth of its Primecare platform and related ventures, with future announcements anticipated regarding new reseller relationships, patient outreach programs, and proprietary health technologies. About Global Technologies, LTD Global Technologies, LTD (OTCPK: GTLL) is a public, multi-operational company committed to building scalable businesses in digital health, wellness, and technology. Through acquisitions, strategic licensing, and integrated platforms, GTLL delivers innovative solutions to improve lives and expand shareholder value. Forward Looking Statements: Statements made in this press release that express the Company or management's intentions, plans, beliefs, expectations or predictions of future events, are forward-looking statements. The words 'believe,' 'expect,' 'intend,' 'estimate,' 'anticipate,' 'will' and similar expressions are intended to further identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Those statements are based on many assumptions and are subject to many known and unknown risks, uncertainties and other factors that could cause the Company's actual activities, results or performance to differ materially from those anticipated or projected in such forward-looking statements. The Company cannot guarantee future financial results; levels of activity, performance or achievements and investors should not place undue reliance on the Company's forward-looking statements. No information contained in this press release should be construed as any indication whatsoever of the Company's future financial performance, future revenues or its future stock price. The forward-looking statements contained herein represent the judgment of the Company as of the date of this press release, and the Company expressly disclaims any intent, obligation or undertaking to update or revise such forward-looking statements to reflect any change in the Company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. No information in this press release should be construed as any indication whatsoever of the Company's future revenues or results of operations. Investor Contact: Wyatt Flippen, CEO and Chairman of the Board [email protected]
USA Today
15-05-2025
- USA Today
An estimated $60K in cigarettes seized from cruise passengers in California
An estimated $60K in cigarettes seized from cruise passengers in California Show Caption Hide Caption FDA proposes cutting nicotine in cigarettes by more than half The FDA has proposed caps on nicotine in cigarettes. The potential rule could reduce the concentration of nicotine in cigarettes by more than half. Scripps News CBP confiscated approximately 750 cartons of illicit cigarettes from two cruise passengers in Long Beach. The cigarettes, lacking necessary permits and FDA-compliant labels, were discovered in the passengers' luggage after arriving from Ensenada, Mexico. The estimated value of the contraband cigarettes is $59,920, and they will be destroyed. U.S. Customs and Border Protection seized nearly 750 cartons of illegally imported cigarettes from two cruise passengers in Long Beach, California. Officers found the cigarettes, including Newport 100s, Marlboro Red, Marlboro Silver and other varieties, in 10 pieces of luggage during an April 17 inspection, according to a May 14 news release. The couple had arrived from Ensenada, Mexico on a cruise. The agency did not identify the travelers or the cruise line they were sailing with. 'Large quantities of cigarettes are considered 'commercial' not personal use; therefore, an importer permit from the U.S. Alcohol and Tobacco Tax and Trade Bureau (TTB) is required,' CBP said in the release. 'In addition, tobacco product labels must meet FDA standards, such as including nicotine warnings and accurate product descriptions.' The two women had receipts for the cigarettes but could not show the required permits. CBP estimated the cartons – which will be destroyed under the agency's supervision – to be valued at $59,920. 'Selling illegally imported cigarettes could yield high profits for underground vendors due to the low cost of cigarettes when purchased overseas and the evasion of taxes owed upon import,' added Africa R. Bell, CBP Port Director of Los Angeles/Long Beach Seaport. 'This type of scheme not only evades revenue owed to the United States but may be harmful to the American consumer.' The news comes after CBP said in late April that officers had seized close to 72 grams of heroin mixed with fentanyl from a cruise passenger arriving in Galveston, Texas. Nathan Diller is a consumer travel reporter for USA TODAY based in Nashville. You can reach him at ndiller@
Yahoo
13-05-2025
- Business
- Yahoo
OncoCyte Corp (OCX) Q1 2025 Earnings Call Highlights: Strategic Advances in Transplant Testing ...
Release Date: May 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. OncoCyte Corp (NASDAQ:OCX) has finalized its clinical trial design and received central IRB approval, marking a significant milestone in its strategic pivot towards transplant rejection testing. The company is on track to submit a data package to the FDA by the end of the year, with FDA approval targeted for the first half of 2026. There is strong interest from top transplant centers in the US and Germany to participate in the clinical trial, representing nearly 10% of US transplant volumes. OncoCyte Corp (NASDAQ:OCX) has successfully expanded its RUO assay to 10 sites across the US, Germany, UK, Switzerland, Austria, and Southeast Asia, with researchers exploring new applications for the tests. The company reported Pharma Services revenue of $2.1 million, exceeding expectations and extending its cash runway, with gross margins of 62%. Pharma Services revenue is situation-driven and expected to vary, with Q2 revenue anticipated to be less than $500,000, highlighting potential revenue volatility. The company's oncology pipeline, while promising, is still in the early stages compared to its transplant focus, indicating a longer timeline for revenue generation in this area. OncoCyte Corp (NASDAQ:OCX) is undergoing a corporate rename, which, although budget-conscious, may cause temporary brand recognition challenges. The company anticipates a couple of quarters with increased cash burn due to clinical trial costs and FDA-compliant software development, impacting financial stability. There is uncertainty regarding the speed at which transplant centers will adopt the new test post-FDA approval, as these centers are generally risk-averse and may require time to integrate new technologies. Warning! GuruFocus has detected 6 Warning Signs with OCX. Q: Can you expand on the interest from a larger pharma customer regarding oncology kits? A: Josh Riggs, CEO: The interest is primarily around Determa IO and its potential as a standalone PCR assay or in conjunction with a larger NGS panel. The data is seen as differentiating, especially in challenging cancers like colon cancer. Q: What are the next milestones for Determa IO, and when might it represent a tangible revenue opportunity? A: Josh Riggs, CEO: We submitted for reimbursement in December 2022 and are awaiting results. The SWAG study, involving 800 patients, is a significant milestone, with results expected towards the end of the year, potentially at the San Antonio Breast Cancer Symposium. Q: What feedback have you received from large US transplant centers about participating in your study? A: Josh Riggs, CEO: The centers are enthusiastic and eager to access the technology. They are interested in answering complex questions that are difficult with only send-out options. The partnership approach is fostering strong relationships. Q: How do you anticipate the iota model impacting market growth? A: Josh Riggs, CEO: The model is expected to increase demand for testing as more marginal organs are used, leading to more adverse events. This will drive the need for tools to manage patients, and we are hopeful that new drugs will mitigate some negative effects. Q: What is the focus of the final Q-sub meeting with the FDA, and what has been de-risked? A: Ecky Schutz, Chief Science Officer: We are submitting the CSA to the FDA and have had productive pre-meetings. The FDA has provided clear guidance on what they want to see, which we have incorporated into our QA. We are on track to submit by the end of the year. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
